TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02580019

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human umbilical cord mesenchymal stem cells
Description: A single dose of 2×107 hUC-MSC will treated to patients, IV, Repeat every weeks for four times.
Study: NCT02215200

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-Thymocyte Globulin (ATG)
Description: Thymoglobulin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granulocyte colony stimulating factor (GCSF)
Description: Granulocyte colony stimulating factor (GCSF)
Study: NCT06584773

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: mTORi added as the fourth maintenance immunosuppressive drug in recipients

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard maintenance immunosuppression
Description: standard maintenance immunosuppression: tacrolimus, mycophenolate, prednisone
Study: NCT02462746

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: L-Cysteine
Description: The trade name is New Root Herbal Inc.
Study: NCT03771378

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhTPO
Description: After enrollment, all subjects receive TPO, the dose is 300 U / Kg, s.c. qd, blood routine examination is detected every 3 days during treatment. If the platelet count \> 250 × 109 / L, the drug will stop until the platelet count ≤ 100 × 109 / L. Efficacy and safety will be evaluated on day 15. The evaluation criteria were based on the consensus of ITP. At the same time, all subjects will receive a mimetic (tablet), po, qd.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: eltrombopag
Description: After enrollment, all subjects receive eltrombopag, the dose is 25 mg/day, po, qd. blood routine examination is detected every 3 days during treatment. If the platelet count \> 250 × 109 / L, the drug will stop until the platelet count ≤ 100 × 109 / L. Efficacy and safety will be evaluated on day 15. The evaluation criteria were based on the consensus of ITP. At the same time, all subjects will give a mimetic (injection), at a dose of 300 U/Kg, s.c. qd.
Study: NCT01370564

Intervention type: DRUG
Group type: OTHER
Intervention: Diuretics
Description: Daily adjustments of diuretics and associated supplements based on cardiac filling pressures.
Study: NCT03787394

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: adding taste enhancer
Description: Comparing sensory profiles of food products either enriched with FAAA-conjugates or plain

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: adding taste enhancer
Description: Comparing sensory profiles of food products either enriched with FAAA-conjugates or plain
Study: NCT01738048

Intervention type: PROCEDURE
Intervention: Reconstruction
Description: Reconstructive surgery after mastectomy, either by expander or autologous tissue. Includes both primary and secondary reconstruction
Study: NCT02907021

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: standard-of-care treatments for LV impairment
Description: Treat patients with mild or moderate LV impairment by standard-of-care treatments for LV impairment using ACE-I and beta-blockers
Study: NCT01605617

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fesoterodine fumarate
Description: PTNS + 4mg of fesoterodine fumarate for 12 weeks
Study: NCT03711799

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Access to services via peer coaching
Description: This intervention will allow for half of the participants, randomly selected, to get help navigating the system of acquiring services for their child. These participants will be assisted by a coach who are also parents of a child with autism and have already been through the process.
Study: NCT02215200

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for ATG)
Description: Normal saline administered by IV infusion to mimic ATG

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (for GCSF)
Description: Placebo prepared to mimic 6mg subcutaneous injection of GCSF

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for GCSF)
Description: Placebo prepared to mimic 6mg subcutaneous injection of GCSF
Study: NCT01605617

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fesoterodine fumarate
Description: PTNS + 4mg of fesoterodine fumarate for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: PTNS + placebo for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: PTNS + placebo for 12 weeks

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous Tibial Nerve Stimulation (PTNS)
Description: PTNS is an FDA-approved procedure for the diagnosis of overactive bladder, given on a weekly basis. Participants will be given PTNS + either 4mg of fesoterodine fumarate or placebo for 12 weeks, and followed by 4 weeks of washout followed by 12 weeks of PTNS + the opposite treatment (placebo or fesoterodine fumarate).

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Percutaneous Tibial Nerve Stimulation (PTNS)
Description: PTNS is an FDA-approved procedure for the diagnosis of overactive bladder, given on a weekly basis. Participants will be given PTNS + either 4mg of fesoterodine fumarate or placebo for 12 weeks, and followed by 4 weeks of washout followed by 12 weeks of PTNS + the opposite treatment (placebo or fesoterodine fumarate).
Study: NCT04272281

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: medical shared decision
Description: The experimental group will use the share decision making tool during consultation to adapt antibiotherapy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard medical care
Description: control group will act as usual in their practice.
Study: NCT02935335

Intervention type: DRUG
Intervention: Menotrophin
Study: NCT02576067

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose methotrexate
Description: Study participants will additionally receive 1 mg daily oral folate.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01512862

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcitriol
Description: Dosage of 0.25 mcg administered orally once daily for 6 weeks and dose escalated to 0.5 mcg orally once daily up to 6 months

Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: Placebo
Description: Dosage of 0.25 mcg administered orally once daily for 6 weeks and dose escalated to 0.5 mcg orally once daily up to 6 months
Study: NCT04700293

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: AYMES AMSTERDAM
Description: AYMES AMSTERDAM is a Food for Special Medical Purposes (FSMP) and must, therefore, be used under medical supervision. It is not designed as a sole source of nutrition.
Study: NCT00868439

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: patiromer
Description: Active investigational drug

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT02691949

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Description: mycophenolate mofetil 1# BID-2# BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Description: mycophenolate mofetil 1# BID-2# BID
Study: NCT02352558

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone will be taken orally at a dose level of 40 mg once weekly, on Days 1, 8, 15, and 22 of each Cycle. Patients over the age of 75 years are allowed to begin dexamethasone at a dose of 20 mg once weekly, on Days 1, 8, 15, and 22 of each Cycle. Dexamethasone should be taken with food or milk, and a minimum of 2 hours should separate a dose of dexamethasone from a dose of BBI608.
Study: NCT00016978

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Study: NCT01142154

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prodarsan
Description: Prodarsan TID, oral solution, 6-8 days
Study: NCT02465775

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: UltraShape treatment
Description: Fat cell destruction is achieved by ultrasound-induced mechanical effects during a very short exposure time.
Study: NCT00598858

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given PO
Study: NCT00117650

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Ad2/HIF-1α/VP16
Description: a one time treatment of 20 IM injections of 0.01 ML each into each leg for a total of 40 injections

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Ad2/HIF-1α/VP16
Description: one time treatment of 20 IM injections of 0.01 ML each into each leg for a total of 40 injections.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Ad2/HIF-1α/VP16
Description: a one time treatment of 20 IM injections of 0.01 ML each into each leg for a total of 40 injections.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline (Placebo Control)
Description: a one time treatment of 20 IM injections of 0.01 ML each into each leg for a total of 40 injections.
Study: NCT02181400

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ellex Integre NIR laser
Description: Each NIR light treatment will consist of a 90 second exposure of the macula of the study eye to the Ellex Integre NIR laser with the patient fixating on the central aiming beam. The laser light beam is 4.5mm in diameter with a central masked area of 1.0 mm diameter containing the central fixation target. In this way the central macula will be spared in the event of an adverse effect of the laser, which we do not anticipate.~The patient will be seated at the slit lamp laser delivery system and after the eye has been dilated and anesthetised with topical eye drops a standard fundus contact lens will be placed on the eye through which the post area pole will be visualised while the treatment is delivered. There will be 12 treatments administered over a 5 week period.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ellex Integre NIR laser
Description: Each NIR light treatment will consist of a 90 second exposure of the macula of the study eye to the Ellex Integre NIR laser with the patient fixating on the central aiming beam. The laser light beam is 4.5mm in diameter with a central masked area of 1.0 mm diameter containing the central fixation target. In this way the central macula will be spared in the event of an adverse effect of the laser, which we do not anticipate.~The patient will be seated at the slit lamp laser delivery system and after the eye has been dilated and anesthetised with topical eye drops a standard fundus contact lens will be placed on the eye through which the post area pole will be visualised while the treatment is delivered. There will be 12 treatments administered over a 5 week period.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ellex Integre NIR laser
Description: Each NIR light treatment will consist of a 90 second exposure of the macula of the study eye to the Ellex Integre NIR laser with the patient fixating on the central aiming beam. The laser light beam is 4.5mm in diameter with a central masked area of 1.0 mm diameter containing the central fixation target. In this way the central macula will be spared in the event of an adverse effect of the laser, which we do not anticipate.~The patient will be seated at the slit lamp laser delivery system and after the eye has been dilated and anesthetised with topical eye drops a standard fundus contact lens will be placed on the eye through which the post area pole will be visualised while the treatment is delivered. There will be 12 treatments administered over a 5 week period.
Study: NCT03928171

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intra-abdominal pressure during laparoscopy
Description: Insufflation pressure of the abdomen during laparoscopy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intra-abdominal pressure during laparoscopy
Description: Insufflation pressure of the abdomen during laparoscopy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intra-abdominal pressure during laparoscopy
Description: Insufflation pressure of the abdomen during laparoscopy
Study: NCT04299581

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: a PD-1 immune check inhibitor

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: US/CT-guided Percutaneous Cryoablation
Description: Cryoablation will be performed with a two-cycle freeze-thaw phase protocol; US or non-contrast CT images will be obtained to visualize the evolving ablation zone
Study: NCT03071900

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: circulating tumor cell analysis
Description: Detect circulating tumor cells with CellCollector in SCCHN and control group.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: circulating tumor cell analysis
Description: Detect circulating tumor cells with CellCollector in SCCHN and control group.
Study: NCT03168009

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bariatric Surgery
Description: Patients will undergo bariatric surgery as routinely scheduled. The type of bariatric procedure will be suggested by the surgeon based on clinical considerations.
Study: NCT01299441

Intervention type: DEVICE
Intervention: ECOM ETT
Description: Intubation with ECOM endotracheal tube (ETT)
Study: NCT00579475

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mifegyne
Description: tablets, 50 mg every other day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT02468882

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Watercress
Description: 100g of watercress daily during radiation therapy
Study: NCT00587899

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Pulmonary Vein Isolation
Description: The treatment group will undergo operation for mitral valve disease with an additional procedure called Pulmonary Vein Isolation using a device that delivers radiofrequency energy to the heart muscle in order to create scar tissue to block electrical impulses that can trigger episodes of AF.
Study: NCT04117334

Intervention type: OTHER
Intervention: Bracing
Study: NCT04357587

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg intravenously (IV) on days 1, 22, and 43

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External beam radiation
Description: Daily fractions of 200 cGy, 5 days a week for the first 5 weeks of the study, excluding weekends

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 825 mg/m2 orally twice a day on days where radiation therapy is given
Study: NCT02135588

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination TISSUE PLASMINOGEN ACTIVATOR (TPA) AND DORNASE ALFA (DNASE)
Study: NCT02599376

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LiDCOrapid
Description: Cardiac output will be non invasively monitored by using 2 cuffs on fingers.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LiDCOrapid
Description: Cardiac output will be non invasively monitored by using 2 cuffs on fingers.
Study: NCT04486742

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Itch CBT
Description: Telemedicine CBT sessions with a therapist to address atopic dermatitis related concerns.
Study: NCT00365183

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Motexafin gadolinium and pemetrexed
Description: 1 dose of MGd 15 mg/kg and pemetrexed 500 mg/m2 once during the first week of every 3-week treatment cycle for a maximum of 12 cycles
Study: NCT03662854

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hair Stimulating Complex (HSC)
Description: Patients will receive 2 mL of HSC separated by 6 weeks (total of 4 mL of HSC)
Study: NCT02352558

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib will be administered at 1.3 mg/m2/dose as a 3-5 second bolus intravenous (IV) injection or subcutaneous injection twice weekly for 2 weeks (Day 1, 4, 8, and 11) followed by a 10-day rest period (Day 12-21).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib
Description: Imatinib will be taken orally once daily with a meal and a large glass of water. For patients having difficulty swallowing, imatinib can be dissolved in water or apple juice for intake. The dose of imatinib is 400 mg for CML patients in the chronic phase and 600 mg for CML patients in the accelerated phase or in blast crisis. A minimum of 2 hours should separate a dose of imatinib from a dose of BBI608.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Ibrutinib will be taken orally once daily with water. Do not open, break, or chew the capsules. The dose of ibrutinib is 420 mg for patients with normal liver function and is 140 mg for patients with mild liver impairment (Child-Pugh class A). A minimum of 2 hours should separate a dose of ibrutinib from a dose of BBI608.
Study: NCT02322671

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reference Montelukast
Description: It is available as pink, round, bi-convex-shaped chewable tablet of reference 5 mg montelukast sodium (innovator product). that has to be placed on the tongue and chewed immediately.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reference Montelukast
Description: It is available as pink, round, bi-convex-shaped chewable tablet of reference 5 mg montelukast sodium (innovator product). that has to be placed on the tongue and chewed immediately.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reference Montelukast
Description: It is available as pink, round, bi-convex-shaped chewable tablet of reference 5 mg montelukast sodium (innovator product). that has to be placed on the tongue and chewed immediately.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reference Montelukast
Description: It is available as pink, round, bi-convex-shaped chewable tablet of reference 5 mg montelukast sodium (innovator product). that has to be placed on the tongue and chewed immediately.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reference Montelukast
Description: It is available as pink, round, bi-convex-shaped chewable tablet of reference 5 mg montelukast sodium (innovator product). that has to be placed on the tongue and chewed immediately.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reference Montelukast
Description: It is available as pink, round, bi-convex-shaped chewable tablet of reference 5 mg montelukast sodium (innovator product). that has to be placed on the tongue and chewed immediately.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test 1 Montelukast
Description: It will be provided as pink, round, bi-convex-shaped chewable tablet of test formulation 1: 5mg montelukast sodium (GW483100) that has to be placed on the tongue and chewed immediately.
Study: NCT02724657

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Buteyko Method
Description: Intervention will be held twice a week during 3 weeks.
Study: NCT02322671

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test 1 Montelukast
Description: It will be provided as pink, round, bi-convex-shaped chewable tablet of test formulation 1: 5mg montelukast sodium (GW483100) that has to be placed on the tongue and chewed immediately.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test 1 Montelukast
Description: It will be provided as pink, round, bi-convex-shaped chewable tablet of test formulation 1: 5mg montelukast sodium (GW483100) that has to be placed on the tongue and chewed immediately.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test 1 Montelukast
Description: It will be provided as pink, round, bi-convex-shaped chewable tablet of test formulation 1: 5mg montelukast sodium (GW483100) that has to be placed on the tongue and chewed immediately.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test 1 Montelukast
Description: It will be provided as pink, round, bi-convex-shaped chewable tablet of test formulation 1: 5mg montelukast sodium (GW483100) that has to be placed on the tongue and chewed immediately.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test 1 Montelukast
Description: It will be provided as pink, round, bi-convex-shaped chewable tablet of test formulation 1: 5mg montelukast sodium (GW483100) that has to be placed on the tongue and chewed immediately.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test 2 Montelukast
Description: It will be provided as pink, round, bi-convex-shaped chewable tablet of test formulation 2: 5mg montelukast sodium (GW483100) that has to be placed on the tongue and chewed immediately.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test 2 Montelukast
Description: It will be provided as pink, round, bi-convex-shaped chewable tablet of test formulation 2: 5mg montelukast sodium (GW483100) that has to be placed on the tongue and chewed immediately.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test 2 Montelukast
Description: It will be provided as pink, round, bi-convex-shaped chewable tablet of test formulation 2: 5mg montelukast sodium (GW483100) that has to be placed on the tongue and chewed immediately.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test 2 Montelukast
Description: It will be provided as pink, round, bi-convex-shaped chewable tablet of test formulation 2: 5mg montelukast sodium (GW483100) that has to be placed on the tongue and chewed immediately.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test 2 Montelukast
Description: It will be provided as pink, round, bi-convex-shaped chewable tablet of test formulation 2: 5mg montelukast sodium (GW483100) that has to be placed on the tongue and chewed immediately.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test 2 Montelukast
Description: It will be provided as pink, round, bi-convex-shaped chewable tablet of test formulation 2: 5mg montelukast sodium (GW483100) that has to be placed on the tongue and chewed immediately.
Study: NCT02995772

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aromatase Inhibitors (Arimidex)
Description: Comparison of efficacy with chemotherapy
Study: NCT01434160

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Skyla (Levonorgestrel, BAY86-5028)
Description: Levonorgestrel intrauterine contraceptive system (LCS12) insertion into the uterus at insertion visit 2 with the study treatment of 12 months. An optional follow up phase up to 3 years will be offered for all subjects completing 12 month treatment time.